Benzinga - U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording gains in today’s session.
- SkyWater Technology, Inc. (NASDAQ: SKYT) jumped 20.1% to $13.73 after the company posted better-than-expected Q4 results.
- Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) shares rose 19% to $4.32 after the company announced it will acquire the Phase 2 program for 225Ac-PSMA I&T, a radiopharmaceutical targeting metastatic castrate resistant prostate cancer.
- FLJ Group Limited (NASDAQ: FLJ) gained 15.2% to $2.12.
- Palantir Technologies Inc. (NYSE: PLTR) surged 14.3% to $8.69 after the company reported better-than-expected fourth-quarter financial results. The company also issued first-quarter and FY23 guidance.
- Genius Brands International, Inc. (NASDAQ: GNUS) shares rose 12.8% to $4.06 after the company announced an exclusive deal with BuzzFeed.
- Oscar Health, Inc. (NYSE: OSCR) gained 12.2% to $5.94. Goldman Sachs and Cowen & Co. raised their price targets on the stock.
- Marathon Digital Holdings, Inc. (NASDAQ: MARA) jumped 11.5% to $6.53.
- Opendoor Technologies Inc. (NASDAQ: OPEN) climbed 10% to $2.2100. Citigroup maintained Opendoor Technologies with a Neutral and raised the price target from $1.5 to $2.
- Cipher Mining Inc. (NASDAQ: CIFR) rose 9.4% to $1.52.
- Embecta Corp. (NASDAQ: EMBC) surged 9.2% to $31.05 following upbeat quarterly results.
- Vicarious Surgical Inc. (NYSE: RBOT) rose 9.1% to $3.36 following upbeat quarterly earnings.
- Avis Budget Group, Inc. (NASDAQ: CAR) gained 8.9% to $240.18 after the company reported better-than-expected fourth-quarter financial results.
- monday.com Ltd. (NASDAQ: MNDY) jumped 8.7% to $158.10. Monday.Com reported fourth-quarter FY22 revenue growth of 57% year-on-year to $149.9 million, beating the consensus of $141.2 million. Several analysts raised their price targets on the stock.
- Kodiak Sciences Inc. (NASDAQ: KOD) gained 8.1% to $7.80.
- Zoetis Inc. (NYSE: ZTS) rose 7% to $174.52 after the company reported better-than-expected Q4 adjusted EPS and sales results and issued FY23 adjusted EPS and revenue guidance above estimates.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.